UNSPSC 51101913: Amodiaquine

This classification denotes an antimalarial agent with the molecular formula C20H22ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 220236ED28, chemically known as 6398-98-7(dihydrochloride, dihydrate) but generally known as amodiaquin, which bears US NIH Compound Identifier 2165. Amodiaquin most often arises in simple, dihydrochloride, and dihyrdate forms. European Medicines Agency schedules Amodiaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05470MIG.

UNSPSC 51101913 Amodiaquine, a Commodity code, nominally names a single antimalarial pharmaceutical product, but recent state and local solicitations tagged under this code show little alignment with that narrow scope. The most recent opportunities involve procurement of naloxone and drug deactivation systems for community health, medical and first aid supplies for fire and rescue operations, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and information-gathering on direct-to-manufacturer prescription programs—none of which center on amodiaquine specifically. State and local buyers posting under this code span county health departments, municipal fire services, cooperative purchasing alliances serving multiple states, and state health and human services commissions. The code appears to serve as a catch-all tag for pharmaceutical and medical supply procurement rather than a precise descriptor of the product line actually being sourced.

Recent activity includes Seminole County, Florida's IFB for naloxone and safe drug deactivation systems (1,900 units of naloxone and 800 systems annually, due July 26, 2023), the City of Tampa's competitive bid for medical and first aid supplies for the Fire Department Rescue Division (169 line items, estimated $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5% bid discount, due March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon (due March 26, 2026), and the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026). Geographic activity spans Florida, Texas, Minnesota, Oregon, and other cooperative purchasing jurisdictions. The code shows mixed application across health departments, municipal emergency services, and state purchasing offices, suggesting this Commodity designation warrants clarification or recoding by the issuing jurisdictions for more precise procurement tracking.